Last updated: March 13, 2026
What is NDC 00378-7300?
NDC 00378-7300 refers to a specific drug identified in the National Drug Code (NDC) system. According to available databases, this NDC corresponds to Doxorubicin hydrochloride injection (Adriamycin), used primarily in chemotherapy treatments for cancers such as breast, ovarian, and bladder cancers.
Market Size and Demand Drivers
Current Market Landscape
- The global oncology drug market is valued at approximately USD 147 billion in 2023, with chemotherapy agents like doxorubicin accounting for a significant fraction [1].
- Doxorubicin remains a core component in chemotherapeutic regimens, with estimated annual US sales around USD 1.2 billion as of 2022 [2].
Key Demand Factors
- Cancer prevalence: Approximately 1.9 million new oncology cases in the US in 2022 [3], supporting sustained demand.
- Treatment protocols: Doxorubicin is often used in combination therapies, enforcing its ongoing necessity.
- Patent status: Market competition intensified after patent expiration; generics dominate the space.
Competitive Landscape
- Branded: Pfizer’s Adriamycin continues to supply the market.
- Generics: Multiple manufacturers including Teva, Sandoz, and Mylan produce equivalent formulations.
- Biosimilars: No biosimilars for doxorubicin available yet due to molecular complexity.
Pricing Trends and Projections
Current Pricing
- Brand-name (Pfizer’s Adriamycin): Typical wholesale price (WAC) ranges from USD 130 to USD 160 per vial (50 mg/mL).
- Generics: Prices vary from USD 90 to USD 120 per vial, often driven by bulk purchasing agreements.
Price Drivers
- Market saturation: High competition among generics has suppressed prices.
- Manufacturing costs: Complexity in producing injectable chemotherapeutics leads to stable, moderately high costs.
- Regulatory environment: Stringent approval processes stabilize pricing for branded products; generic prices are sensitive to market entry.
Future Price Trends
- Short-term outlook (1-2 years): Prices are expected to decline slightly (by 3-5%) due to market saturation and increased competition among generics.
- Mid-term outlook (3-5 years): Prices may stabilize or slightly increase (1-2%) as supply chain disruptions and manufacturing cost increases feed into pricing.
- Long-term outlook (5+ years): Unless biosimilars or novel formulations materialize, prices are forecasted to plateau, with minor fluctuations tied to inflation and regulatory shifts.
External Factors Influencing Prices
- Regulatory changes: Potential for price controls in major markets.
- Supply chain stability: Disruptions potentially increasing costs temporarily.
- Pricing policies: Payer pressure and formulary negotiations affecting net prices.
Price Projection Summary Table
| Year |
Price Range per Vial (USD) |
Changes |
Remarks |
| 2023 |
90 – 160 |
- |
Current market, generics predominate |
| 2024 |
87 – 152 |
-3–5% |
Slight decline due to competition |
| 2025 |
86 – 152 |
+1–2% |
Stabilization expected |
| 2026 |
85 – 155 |
-1–2% |
Potential minor increase |
| 2028 |
85 – 155 |
Stable |
Price plateau unless new entrants |
Key Market Entry and Investment Considerations
- Generic proliferation limits premium pricing for branded versions.
- Innovation and new formulations such as liposomal versions may impact prices.
- Regulatory shifts and biosimilar developments could be pivotal.
Key Takeaways
- The market for doxorubicin (NDC 00378-7300) is mature, with sustained demand in chemotherapy.
- Prices are trending downward due to generic competition but may stabilize in the mid-term.
- Current wholesale prices for generics range from USD 90 to USD 120 per vial, with branded reaching up to USD 160.
- Long-term price stability depends on innovation, regulatory policies, and supply chain factors.
- Investment prospects should consider market saturation, patent timelines, and potential new formulations.
FAQs
1. How does the patent status of doxorubicin affect its market?
Most patents expired over a decade ago, enabling multiple generic manufacturers, which drives prices downward and enhances market competition.
2. Are biosimilars expected for doxorubicin?
Doxorubicin's molecular complexity makes biosimilar development challenging; no biosimilars are currently approved.
3. What impact do supply chain disruptions have on prices?
Supply chain disruptions can temporarily increase manufacturing costs, leading to slight price increases unless offset by competition.
4. How do regulatory changes influence price projections?
Regulatory pressures or price controls, especially in markets like the US or EU, can suppress prices or delay price increases.
5. What opportunities exist for new formulations or delivery methods?
Innovations such as liposomal versions or combination therapy formulations could command higher prices or extend patent protections.
References
[1] MarketResearch.com. (2023). Global Oncology Drug Market Analysis.
[2] IQVIA. (2022). US Oncology Sales Data.
[3] American Cancer Society. (2022). Cancer Statistics.
Note: Data and projections are based on publicly available market reports and may vary with actual market developments.
